True about non-competitive inhibition is

Explanation

## Correct Answer: A. Km remains same, Vmax decreases Non-competitive inhibition occurs when an inhibitor binds to an enzyme at a site *other than* the active site, or binds to both the free enzyme and the enzyme–substrate complex with equal affinity. This mechanism is fundamentally different from competitive inhibition because the inhibitor cannot be outcompeted by increasing substrate concentration. The key discriminator is that non-competitive inhibitors reduce the *maximum velocity* (Vmax) of the enzyme—fewer enzyme molecules are available in their active form—but do *not* change the Michaelis constant (Km). Km reflects the affinity of the enzyme for its substrate at the active site; since the inhibitor binds elsewhere or to a non-catalytic site, the intrinsic affinity of the active site for substrate remains unchanged. In Lineweaver–Burk plots, non-competitive inhibition produces parallel lines (same x-intercept = −1/Km, different y-intercepts = 1/Vmax). Clinically in India, understanding this distinction is critical when interpreting drug interactions—for example, some anticonvulsants and antiretrovirals exhibit non-competitive inhibition of hepatic enzymes, reducing drug clearance without altering substrate affinity. This is why increasing substrate (or drug) dose cannot overcome non-competitive inhibition, unlike competitive inhibition where high substrate concentration can restore enzyme activity. ## Why the other options are wrong **B. Km increases, Vmax remains same** — This describes *competitive* inhibition, not non-competitive. In competitive inhibition, the inhibitor competes with substrate for the active site, so apparent Km increases (higher substrate needed to achieve half-maximal velocity), but Vmax is unchanged because excess substrate can displace the inhibitor. This is the most common NBE trap—students confuse the two mechanisms. **C. Km increases, Vmax increases** — This is biochemically impossible under normal enzyme kinetics. Both parameters increasing simultaneously does not correspond to any recognized inhibition mechanism. This is a distractor designed to catch students guessing or misremembering Michaelis–Menten relationships. **D. Km decreases, Vmax increases** — This pattern is opposite to inhibition and would suggest enzyme *activation* or allosteric enhancement. Non-competitive inhibition always reduces Vmax; it never increases it. This option exploits confusion about the direction of inhibitory effects. ## High-Yield Facts - **Non-competitive inhibition**: Km unchanged, Vmax decreased—inhibitor binds to site other than active site. - **Competitive inhibition**: Km increased, Vmax unchanged—inhibitor competes with substrate for active site; overcome by ↑ substrate. - **Lineweaver–Burk plot for non-competitive**: Parallel lines (same x-intercept, different y-intercepts). - **Lineweaver–Burk plot for competitive**: Lines intersect on y-axis (same y-intercept, different x-intercepts). - **Clinical relevance**: Non-competitive inhibition cannot be overcome by increasing substrate/drug dose—critical for drug interaction management in Indian polypharmacy settings. ## Mnemonics ****COMP vs NON-COMP**** **COMP**etitive = **COMP**etes for active site → Km ↑, Vmax same. **NON-COMP** = binds elsewhere → Km same, Vmax ↓. Use: When comparing inhibition types on enzyme kinetics questions. ****Lineweaver–Burk Line Behavior**** **Competitive** = lines meet on **Y-axis** (Vmax same). **Non-competitive** = lines are **PARALLEL** (Km same). Use: When asked to identify inhibition type from a Lineweaver–Burk plot. ## NBE Trap NBE pairs non-competitive inhibition with competitive inhibition in the same question set to exploit the high confusion rate between the two mechanisms. Students who memorize "inhibition = Km increases" (true for competitive only) will incorrectly select option B, making this the most common wrong answer. ## Clinical Pearl In Indian hospitals, when a patient on warfarin (substrate for CYP2C9) is started on a non-competitive inhibitor like amiodarone, the INR rises despite unchanged warfarin dose because Vmax of metabolism decreases—you cannot overcome this by increasing warfarin dose (unlike competitive inhibition). This is why therapeutic drug monitoring and dose adjustment are essential in polypharmacy. _Reference: KD Tripathi Pharmacology Ch. 1 (General Pharmacology: Enzyme Kinetics); Guyton & Hall Textbook of Medical Physiology Ch. 4 (Transport of Substances Through Cell Membrane)_